デフォルト表紙
市場調査レポート
商品コード
1732856

ペニシリン市場- 世界の産業規模、シェア、動向、機会および予測、製品別、タイプ別、投与経路別、エンドユーザー別、地域別、競合別、2020-2030年

Penicillin Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Product, By Type, By Route of Administration, By End User, By Region & Competition, 2020-2030F

出版日
ページ情報
英文 180 Pages
納期
2～3営業日
カスタマイズ可能
ペニシリン市場- 世界の産業規模、シェア、動向、機会および予測、製品別、タイプ別、投与経路別、エンドユーザー別、地域別、競合別、2020-2030年
出版日: 2025年05月23日
発行: TechSci Research
ページ情報: 英文 180 Pages
納期: 2～3営業日
GIIご利用のメリット

  • 全表示

  • 概要
  • 目次
概要

ペニシリンの世界市場は、2024年に101億5,000万米ドルと評価され、2030年には125億8,000万米ドルに達し、CAGR 3.60%で成長すると予測されています。

ペニシリンは約1世紀前に発見されたにもかかわらず、その幅広いスペクトラム活性、費用対効果、永続的な臨床的有用性により、抗菌治療の要であり続けています。特に様々な細菌感染症の治療において、その治療効果と手頃な価格により、その需要は世界中で旺盛な状態が続いています。市場は、抗菌薬耐性菌の増加や新薬との競合といったハードルに直面しているもの、特に新興国地域におけるヘルスケア・インフラの拡大、人口動態の変化、薬剤製剤やデリバリー・メカニズムの継続的な進歩によって支えられています。これらのダイナミクスは、世界の抗生物質市場における長期的な成長とペニシリンの戦略的重要性を支えています。

市場概要
予測期間 2026-2030
市場規模：2024年 101億5,000万米ドル
市場規模：2030年 125億8,000万米ドル
CAGR：2025年～2030年 3.60%
急成長セグメント βラクタマーゼ阻害剤
最大市場 北米

市場促進要因

細菌感染率の上昇

主な市場課題

抗生物質耐性と細菌株の進化

主要市場動向

ドラッグ製剤とデリバリー方法の革新

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 ペニシリン市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 製品別（バルク、投与量）
    • 種類別（アミノペニシリン、抗緑膿菌ペニシリン、βラクタマーゼ阻害剤、その他）
    • 投与経路（経口、筋肉内、静脈内）
    • エンドユーザー別（病院・クリニック、製薬・バイオテクノロジー企業、学術・調査機関）
    • 地域別
    • 企業別（2024）
  • 市場マップ

第6章 北米のペニシリン市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 北米：国別分析
    • 米国
    • カナダ
    • メキシコ

第7章 欧州のペニシリン市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 欧州：国別分析
    • ドイツ
    • 英国
    • イタリア
    • フランス
    • スペイン

第8章 アジア太平洋地域のペニシリン市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • アジア太平洋地域：国別分析
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア

第9章 南米のペニシリン市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカのペニシリン市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 中東・アフリカ：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 最近の動向
  • 製品上市
  • 合併と買収

第13章 世界のペニシリン市場：SWOT分析

第14章 競合情勢

  • Astellas Pharma Inc.
  • Novartis International AG
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Merck Co. & Inc.
  • F.Hoffmann-La Roche Ltd.
  • Toyama Chemical Co., Ltd.
  • Sanofi Aventis SA
  • MiddleBrook Pharmaceuticals, Inc.
  • Gilead Sciences Inc.

第15章 戦略的提言

第16章 調査会社について・免責事項

目次
Product Code: 14275

The Global Penicillin Market was valued at USD 10.15 Billion in 2024 and is projected to reach USD 12.58 Billion by 2030, growing at a CAGR of 3.60%. Despite its discovery nearly a century ago, penicillin remains a cornerstone of antibacterial therapy due to its broad-spectrum activity, cost-effectiveness, and enduring clinical utility. Its demand continues to be strong worldwide, driven by its therapeutic efficacy and affordability, particularly in treating various bacterial infections. Although the market faces hurdles such as rising antimicrobial resistance and competition from newer drugs, it is bolstered by expanding healthcare infrastructure, especially in developing regions, demographic shifts, and continuous advancements in drug formulations and delivery mechanisms. These dynamics collectively support the long-term growth and strategic importance of penicillin in the global antibiotic landscape.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 10.15 Billion
Market Size 2030USD 12.58 Billion
CAGR 2025-20303.60%
Fastest Growing SegmentBeta-Lactamase Inhibitor
Largest MarketNorth America

Key Market Drivers

Rising Prevalence of Bacterial Infections

The increasing incidence of bacterial infections significantly propels the growth of the Global Penicillin Market. A recent global health review found that bacterial infections, excluding tuberculosis, accounted for 7.7 million deaths worldwide-13.6% of all deaths-underscoring the critical need for effective antibiotics. Penicillin remains a primary treatment for various infections including respiratory tract conditions like pneumonia and bronchitis, skin and soft tissue infections, UTIs, streptococcal and staphylococcal infections, and STDs such as syphilis. These infections are particularly widespread in low- and middle-income countries, where access to clean water, sanitation, and healthcare is limited. Given its effectiveness against many such pathogens, penicillin's demand continues to rise in alignment with global infection rates.

Key Market Challenges

Antibiotic Resistance and Evolving Bacterial Strains

The escalating issue of antibiotic resistance represents a major challenge to the penicillin market. Misuse and overuse of antibiotics have led to resistant strains like Penicillin-resistant Streptococcus pneumoniae and MRSA, reducing the drug's effectiveness. This has compelled healthcare professionals to opt for more advanced and often costlier antibiotics. In turn, this shift impacts penicillin's market share and has led to stricter regulatory measures and antibiotic stewardship programs aimed at curbing inappropriate prescriptions, thereby restraining market growth.

Key Market Trends

Innovation in Drug Formulations and Delivery Methods

The penicillin market is experiencing growth through advancements in drug formulations and delivery systems. Novel developments like extended-release injectables, child-friendly suspensions, and combination therapies are enhancing patient adherence, broadening clinical applications, and minimizing side effects. These innovations are critical in maintaining penicillin's relevance against rising resistance, improving therapeutic outcomes, and opening up new segments, including neonatal and elderly care, thus driving further market expansion.

Key Market Players

  • Astellas Pharma Inc.
  • Novartis International AG
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Merck Co. & Inc.
  • F.Hoffmann-La Roche Ltd.
  • Toyama Chemical Co., Ltd.
  • Sanofi Aventis SA
  • MiddleBrook Pharmaceuticals, Inc.
  • Gilead Sciences Inc

Report Scope:

In this report, the Global Penicillin Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Penicillin Market, By Product:

  • Bulk
  • Dosage

Penicillin Market, By Type:

  • Aminopenicillin
  • Antipseudomonal Penicillin
  • Beta Lactamase Inhibitor
  • Others

Penicillin Market, By Route of Administration:

  • Oral
  • Intramuscular
  • Intravenous

Penicillin Market, By End User:

  • Hospitals & Clinics
  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutions

Penicillin Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Penicillin Market.

Available Customizations:

Global Penicillin market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Penicillin Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Bulk, Dosage)
    • 5.2.2. By Type (Aminopenicillin, Antipseudomonal Penicillin, Beta Lactamase Inhibitor, Others)
    • 5.2.3. By Route of Administration (Oral, Intramuscular, Intravenous)
    • 5.2.4. By End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Academic & Research Institutions)
    • 5.2.5. By Region
    • 5.2.6. By Company (2024)
  • 5.3. Market Map

6. North America Penicillin Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Type
    • 6.2.3. By Route of Administration
    • 6.2.4. By End User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Penicillin Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Type
        • 6.3.1.2.3. By Route of Administration
        • 6.3.1.2.4. By End User
    • 6.3.2. Canada Penicillin Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Type
        • 6.3.2.2.3. By Route of Administration
        • 6.3.2.2.4. By End User
    • 6.3.3. Mexico Penicillin Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Type
        • 6.3.3.2.3. By Route of Administration
        • 6.3.3.2.4. By End User

7. Europe Penicillin Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Type
    • 7.2.3. By Route of Administration
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Penicillin Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Type
        • 7.3.1.2.3. By Route of Administration
        • 7.3.1.2.4. By End User
    • 7.3.2. United Kingdom Penicillin Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Type
        • 7.3.2.2.3. By Route of Administration
        • 7.3.2.2.4. By End User
    • 7.3.3. Italy Penicillin Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Type
        • 7.3.3.2.3. By Route of Administration
        • 7.3.3.2.4. By End User
    • 7.3.4. France Penicillin Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Type
        • 7.3.4.2.3. By Route of Administration
        • 7.3.4.2.4. By End User
    • 7.3.5. Spain Penicillin Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Type
        • 7.3.5.2.3. By Route of Administration
        • 7.3.5.2.4. By End User

8. Asia-Pacific Penicillin Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Type
    • 8.2.3. By Route of Administration
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Penicillin Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Type
        • 8.3.1.2.3. By Route of Administration
        • 8.3.1.2.4. By End User
    • 8.3.2. India Penicillin Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Type
        • 8.3.2.2.3. By Route of Administration
        • 8.3.2.2.4. By End User
    • 8.3.3. Japan Penicillin Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Type
        • 8.3.3.2.3. By Route of Administration
        • 8.3.3.2.4. By End User
    • 8.3.4. South Korea Penicillin Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Type
        • 8.3.4.2.3. By Route of Administration
        • 8.3.4.2.4. By End User
    • 8.3.5. Australia Penicillin Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Type
        • 8.3.5.2.3. By Route of Administration
        • 8.3.5.2.4. By End User

9. South America Penicillin Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Type
    • 9.2.3. By Route of Administration
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Penicillin Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Type
        • 9.3.1.2.3. By Route of Administration
        • 9.3.1.2.4. By End User
    • 9.3.2. Argentina Penicillin Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Type
        • 9.3.2.2.3. By Route of Administration
        • 9.3.2.2.4. By End User
    • 9.3.3. Colombia Penicillin Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Type
        • 9.3.3.2.3. By Route of Administration
        • 9.3.3.2.4. By End User

10. Middle East and Africa Penicillin Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Type
    • 10.2.3. By Route of Administration
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Penicillin Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Type
        • 10.3.1.2.3. By Route of Administration
        • 10.3.1.2.4. By End User
    • 10.3.2. Saudi Arabia Penicillin Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Type
        • 10.3.2.2.3. By Route of Administration
        • 10.3.2.2.4. By End User
    • 10.3.3. UAE Penicillin Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Type
        • 10.3.3.2.3. By Route of Administration
        • 10.3.3.2.4. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Penicillin Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. Astellas Pharma Inc.
    • 14.1.1. Business Overview
    • 14.1.2. Product & Service Offerings
    • 14.1.3. Recent Developments
    • 14.1.4. Financials (If Listed)
    • 14.1.5. Key Personnel
    • 14.1.6. SWOT Analysis
  • 14.2. Novartis International AG
  • 14.3. GlaxoSmithKline plc
  • 14.4. Pfizer Inc.
  • 14.5. Merck Co. & Inc.
  • 14.6. F.Hoffmann-La Roche Ltd.
  • 14.7. Toyama Chemical Co., Ltd.
  • 14.8. Sanofi Aventis SA
  • 14.9. MiddleBrook Pharmaceuticals, Inc.
  • 14.10.Gilead Sciences Inc.

15. Strategic Recommendations

16. About Us & Disclaimer